Skip Navigation


Rheumatology Advance Access originally published online on August 22, 2008
Rheumatology 2008 47(10):1587-1588; doi:10.1093/rheumatology/ken347
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
47/10/1587-a    most recent
ken347v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jobanputra, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jobanputra, P.
Related Collections
Right arrow Pharmacology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

LETTERS TO THE EDITOR

BSR DMARD monitoring guidelines: sulfasalazine

P. Jobanputra1

1Department of Rheumatology, University Hospital Birmingham Foundation Trust, Selly Oak Hospital, Birmingham, UK

Correspondence to: P. Jobanputra, Department of Rheumatology, University Hospital Birmingham Foundation Trust, Selly Oak Hospital, Raddlebarn Road, Birmingham, B29 6JD, UK. E-mail: p.jobanputra@bham.ac.uk

The first 10% of the full text of this article appears below.

SIR, Regarding the recommendations for monitoring SSZ, I and my colleagues [1] recently reported a series of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?